US population for 2022 is 332.4 million with an adult
US population for 2022 is 332.4 million with an adult population of 258.3 million. If 30-40% have NAFLD and 3-12% have NASH. Both someday possibly being treatable with a 14 week course of once a week Leronlimab. Or 14 injections at say $1,000 a dose or $14,000 for the 14 week treatment. Some will go longer if actually diagnosed with Nash. Nash patients might have to continue full time treatment until regression or until a liver is transplanted. Some patients may not to have another treatment after with a diet change to avoid and to not regress to NAFLD.
Having a treatment possibility of 30% of 258.3 million adults equals 77,490,000 potential NAFLD/NASH patients. Now what value is that for sales of Leronlimab?
77,490,000 adults with NAFLD at $14,000 per patient cost is $1,084,860,000,000. Or over a trillion dollars and not including full time treatment of the NASH patients who will stay on treatment for either longer or until transplant.
Of course this is the total population of just the USA and treating them would take years to catch up and help these people. When you consider the whole world population is in the same boat…Is there any wonder that every pharmaceutical company has trialed drugs and some multiple drug to treat NASH and NAFLD. The market is the largest treatable disease the world has ever seen. Nothing compares to this. Even Long Hauler’s treatment is no where close but clearly could become the worlds second largest treatment ever attempted when the right drug if found for both these diseases.
Does anyone know of a drug that could possibly treat both NAFLD/NASH and Long Hauler’s? If you do… you might want to pick up a few shares of stock in the company that might have this special drug. I am just say’n… hmmmm… quite the opportunity.
A week ago I doubled my holdings and that’s just me… had not bought any shares since 9/2019. Just seemed like an opportunity that dropped below my original purchase price average of .34/share. Now my average is .29/share and I am prepared to lose it all or travel the world on value realized from Leronlimab. Only time will tell.
Once again this just me and not investment advice. We all need to do our own research and the value of it. Good days ahead is all we hope for. A partnership for NAFLD/NASH could be the beginnings of something big. This is the hope we all have.
7
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
DraftKings' Surprising Turn of Fortune Talk about a gut punch! DraftKings (NASDAQ: DKNG) dropped a bombshell that had investors reeling. They decided to lop off a hefty slice of their revenue guidance, and trust me, those aren't small numbers we’re talking about. On November 6, they yanked their full-year 2026 revenue guidance down to $6.35 billion to $6.55 billion from...
Continue Reading
Portfolio Boost: Adapting to Market Needs If you're sniffing around the windows business, there's a fresh breeze of innovation blowing from Andersen. They're not just sitting around drumming their fingers—they're rolling up their sleeves and fine-tuning their offerings. With half of homeowners swinging a hammer on renovations last year, the company sees an opportunity...
Continue Reading
Investors' Nerves Tested as Tenax Takes a Nosedive Holy smokes! When a biotech company like Tenax Therapeutics, Inc. (NASDAQ: TENX) detonates like a forgotten fireworks stash, investors have every right to get itchy. Tenax’s shocking announcement that their Phase 3 LEVEL trial for TNX-103 flopped has sparked more than just shareholder anxiety. It’s ignited a...
Continue Reading
The Advertising Gala with Heart When you toss nearly 300 advertising honchos into a room at Tribeca's Rooftop, you don't just get another bash; you get an industry checkpoint. This time, the 212NYC shindig on November 5, 2026, wasn't just about stroking egos. It was about spotlighting the soul in business, right when AI threatens to run wild with it. Navigating AI's...
Continue Reading
The Windy City Meets the Diamond Alright, bear with me here. Monday morning vibes, right? But here's something that'll turn your breakfast around if you're into baseball—or just the latest scoop on players making waves in gear. Pete Crow-Armstrong, the Chicago Cubs center fielder who's been lighting up the field, has his name on some fresh gear. We're talking signature...
Continue Reading
Unveiling Vance's High-Powered Backers Brace yourself for a fresh round of political sparring, folks. The Patriots for American Principles PAC has decided that JD Vance's relationships with the billionaire elite need a little more sunshine. And they're not shy about it—Vance's billionaires will be paraded around the streets of Washington D.C. on a mobile billboard,...
Continue Reading
Investing in Koppers: A Mixed Bag in Q3 Well, it appears Koppers (NYSE: KOP) is doing a bit of a dance this quarter—some smooth steps, but a few stumbles in the rhythm when it comes to margins. The hardwood numbers tell an interesting tale, so let's break it down. Sales Edge Up, But Margins Suffer Koppers clocked in net sales of $499.1 million for the third quarter of...
Continue Reading
Precision's Big Reveal at SITC 2026 When it comes to the shifting tides of oncology advancements, Precision Biologics is making some serious waves. They're not leaning back; they're diving right in with their latest showcase at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, 2026. CEO Dr. Philip M. Arlen announced compelling preclinical data for their...
Continue Reading
Everest Group's Legal Spiral: What's Happening? Folks, when a company feels like it's caught in an endless storm, investors better hold on tight. That's the situation Everest Group, Ltd. finds itself in, with an 11.4% stock dive that’s got investors reeling. Securities fraud allegations are rocking Everest like a hurricane, and The Law Offices of Frank R. Cruz have put...
Continue Reading
Hope in Persistence: Cesalatamig in the Spotlight Swinging through the medical landscape like a seasoned fighter, OncoC4's recent revelations at the SITC 2026 give investors and doctors a reason to pay close attention. We're sizing up their investigational drug, cesalatamig, which flaunts a solid objective response rate of 33% among non-small cell lung cancer (NSCLC)...
Continue Reading
Top 5 Most Recently Viewed Articles
Revolutionizing Metal Printing with AI Technology Precision Additive has recently made waves in the manufacturing world by launching its groundbreaking metal additive manufacturing system, known as the PA-300. This innovative printer utilizes cutting-edge laser powder bed fusion (LPBF) technology, setting a new standard for speed and efficiency in the 3D metal printing...
Continue Reading
Introducing the Data Marketplace by data.world data.world has recently launched an innovative Data Marketplace, designed to transform the way business users discover and access high-quality data within their organizations. This new marketplace bridges the gap between the technical intricacies of data catalogs and the everyday needs of non-technical users. The aim is...
Continue Reading
Archer Roose Wines Partners with Princess Cruises Archer Roose Wines, a popular canned wine brand known for its luxury offerings, has teamed up with Princess Cruises to become their first official canned wine partner. This collaboration allows guests on Princess Cruises to enjoy a selection of Archer Roose Wines including Bubbly, Pinot Noir, Rosé, and Sauvignon Blanc...
Continue Reading
CG Cosmetic Surgery's New Aesthetic Solutions CG Cosmetic Surgery and CG Smile are proudly announcing an exciting expansion of their integrated aesthetic solutions, aimed at revolutionizing cosmetic enhancements in the Miami area. This initiative combines state-of-the-art techniques with an unwavering commitment to patient care, bringing a fresh perspective to individuals...
Continue Reading
Back in 2024, BOXX Insurance made waves by teaming up with World Travel Protection to launch Cyber Assist, a service aimed at keeping business travelers safe from cyber threats. You know the deal—cybercrime was on the rise, and this collaboration seemed like a lifeline for folks on the go. Cyber Assist: Shielding Business Travelers from Threats So here’s what went...
Continue Reading